U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H53N2O4.Br
Molecular Weight 609.678
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROCURONIUM BROMIDE

SMILES

[Br-].[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])C[C@H](O)[C@H](C[C@]34C)N5CCOCC5)[N+]6(CC=C)CCCC6

InChI

InChIKey=OYTJKRAYGYRUJK-FMCCZJBLSA-M
InChI=1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-;/m0./s1

HIDE SMILES / InChI

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C32H52N2O4
Molecular Weight 528.7663
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/zemuron-rocuronium-343109 | https://www.drugs.com/pro/rocuronium-bromide-injection.html | https://www.drugbank.ca/drugs/DB00728 | https://www.ncbi.nlm.nih.gov/pubmed/2573387 | https://www.ncbi.nlm.nih.gov/pubmed/21568994

Rocuronium (brand names Zemuron, Esmeron) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anesthesia to facilitate endotracheal intubation by providing skeletal muscle relaxation, most commonly required for surgery or mechanical ventilation. Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium. Most common adverse reactions are transient hypotension and hypertension.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.6 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZEMURON

Approved Use

Rocuronium bromide injection is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium bromide is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. (1)

Launch Date

7.6386238E11
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.4 h
0.6 mg/kg single, intravenous
dose: 0.6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ROCURONIUM unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.9 h
0.45 mg/kg single, intravenous
dose: 0.45 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ROCURONIUM unknown
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
0.6 mg/kg single, intravenous
dose: 0.6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ROCURONIUM unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.15 mg/kg single, intravenous
Recommended
Dose: 0.15 mg/kg
Route: intravenous
Route: single
Dose: 0.15 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 64
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 64
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (14%)
Vomiting (3%)
Sources:
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (14%)
Vomiting (6%)
Procedural hypotension (5%)
Sources:
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (17%)
Vomiting (8%)
Procedural hypotension (5%)
Nausea (5%)
Sources:
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (18%)
Vomiting (12%)
Procedural hypotension (4%)
Nausea (4%)
Sources:
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Other AEs: Procedural pain, Hypercapnia...
Other AEs:
Procedural pain (12%)
Hypercapnia (3%)
Nausea (3%)
Sources:
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
midazolam(1-2 mg)
propofol(1.8 mg/kg)
alfentanil(9 ug/kg)
Sources:
unhealthy, 33.1
n = 20
Health Status: unhealthy
Condition: surgical procedures
Age Group: 33.1
Sex: F
Population Size: 20
Sources:
Other AEs: Nausea and vomiting...
Other AEs:
Nausea and vomiting (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Procedural pain 14%
0.15 mg/kg single, intravenous
Recommended
Dose: 0.15 mg/kg
Route: intravenous
Route: single
Dose: 0.15 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 64
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 64
Sources:
Vomiting 3%
0.15 mg/kg single, intravenous
Recommended
Dose: 0.15 mg/kg
Route: intravenous
Route: single
Dose: 0.15 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 64
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 64
Sources:
Procedural pain 14%
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Procedural hypotension 5%
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Vomiting 6%
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Procedural pain 17%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Nausea 5%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Procedural hypotension 5%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Vomiting 8%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Vomiting 12%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Procedural pain 18%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Nausea 4%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Procedural hypotension 4%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Procedural pain 12%
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Hypercapnia 3%
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Nausea 3%
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Nausea and vomiting 2 patients
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
midazolam(1-2 mg)
propofol(1.8 mg/kg)
alfentanil(9 ug/kg)
Sources:
unhealthy, 33.1
n = 20
Health Status: unhealthy
Condition: surgical procedures
Age Group: 33.1
Sex: F
Population Size: 20
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
yes
PubMed

PubMed

TitleDatePubMed
Muscle relaxants suitable for day case surgery.
2001
Comparison of the influence of desflurane nitrous oxide anesthesia to propofol nitrous oxide anesthesia on rocuronium bromide induced neuromuscular block.
2001
Comparative study of the TOF-ratio measured by the ParaGraph versus the TOF-Guard, with and without thumb repositioning.
2001
Recovery of neuromuscular block in morbidly obese patients following an infusion of rocuronium.
2001
Anaesthetic management of an adolescent for scoliosis surgery with a Fontan circulation.
2001
Recent advances in myorelaxant therapy.
2001
Target controlled infusion of remifentanil and propofol for cesarean section in a patient with multivalvular disease and severe pulmonary hypertension.
2001
Increased sensitivity to depolarization and nondepolarizing neuromuscular blocking agents in young rat hemidiaphragms.
2001 Aug
Transcranial Doppler ultrasonography with induction of anesthesia and neuromuscular blockade in surgical patients.
2001 Aug
[Anesthesia in Prader-Willi syndrome for major surgery for kyphoscoliosis].
2001 Aug-Sep
The new neuromuscular blocking agents: do they offer any advantages?
2001 Dec
[New muscle relaxants].
2001 Dec
Why do we still use suxamethonium for caesarean section?
2001 Dec
[Sevoflurane augments the degree and speeds the onset of rocuronium evoked neuromuscular blockade in children].
2001 Dec
The effect of rocuronium on intraocular pressure: a comparison with succinylcholine.
2001 Dec
Comparison of effects of remifentanil and alfentanil on cardiovascular response to tracheal intubation in hypertensive patients.
2001 Jan
Intubating conditions after three different doses of rocuronium in the elderly.
2001 Jun
Rocuronium: high risk for anaphylaxis?
2001 Nov
Rocuronium and anaphylaxis--a statistical challenge.
2001 Nov
Allergic reactions during anaesthesia - increased attention to the problem in Denmark and Norway.
2001 Nov
Rapid sequence induction: a national survey of practice.
2001 Nov
Precurarization and priming: a theoretical analysis of safety and timing.
2001 Nov
Anaphylaxis during anaesthesia. Results of a two-year survey in France.
2001 Oct
Is succinylcholine appropriate or obsolete in the intensive care unit?
2001 Oct
Huntington's chorea: use of rocuronium.
2001 Oct
Probability of acceptable intubation conditions with low dose rocuronium during light sevoflurane anaesthesia in children.
2001 Sep
Spontaneous movements, local reactions and pain on injection of rocuronium. A comparison between female and male patients.
2001 Sep
Different patterns of mast cell activation by muscle relaxants in human skin.
2001 Sep
Effect of ondansetron pretreatment on pain after rocuronium and propofol injection: a randomised, double-blind controlled comparison with lidocaine.
2001 Sep
Target controlled infusion of rocuronium: selection of a pharmacokinetic model.
2002
An isolated, antegrade, perfused, peroneal nerve anterior tibialis muscle model in the rat: a novel model developed to study the factors governing the time course of action of neuromuscular blocking agents.
2002 Apr
Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships.
2002 Apr 25
Postoperative muscle paralysis after rocuronium: less residual block when acceleromyography is used.
2002 Feb
Resistance to rocuronium in a child with Schwartz-Jampel syndrome type 1 B.
2002 Feb
Effects of rocuronium pretreatment on muscle enzyme levels following suxamethonium.
2002 Feb
Comparison of rocuronium and suxamethonium for rapid tracheal intubation in children.
2002 Feb
Population pharmacodynamic modeling without plasma concentrations of rocuronium in children.
2002 Jan
The detection and identification of quaternary nitrogen muscle relaxants in biological fluids and tissues by ion-trap LC-ESI-MS.
2002 Jan-Feb
Presynaptic inhibitory effects of rocuronium and SZ1677 on [3H]acetylcholine release from the mouse hemidiaphragm preparation.
2002 Jun
Effects of remifentanil and alfentanil on the cardiovascular responses to induction of anaesthesia and tracheal intubation in the elderly.
2002 Mar
[Anaphylaxis after rocuronium: advantage of blood tests for early diagnosis].
2002 Mar
The influence of induction technique on intubating conditions 1 min after rocuronium administration: a comparison of a propofol-ephedrine combination and propofol.
2002 Mar
Impact of shorter-acting neuromuscular blocking agents on fast-track recovery of the cardiac surgical patient.
2002 Mar
The Laryngeal Mask Airway ProSeal(TM) as a temporary ventilatory device in grossly and morbidly obese patients before laryngoscope-guided tracheal intubation.
2002 Mar
Prolonged neuromuscular block after rocuronium in postpartum patients.
2002 Mar
The potency of new muscle relaxants on recombinant muscle-type acetylcholine receptors.
2002 Mar
Pretreatment before succinylcholine for outpatient anesthesia?
2002 Mar
Mild core hypothermia and anesthetic requirement for loss of responsiveness during propofol anesthesia for craniotomy.
2002 May
The neuropathologic effects in rats and neurometabolic effects in humans of large-dose remifentanil.
2002 May
The hemodynamic effects of rapacuronium in patients with coronary artery disease: succinylcholine and vecuronium compared.
2002 May
Patents

Sample Use Guides

0.45-0.6 mg/kg IV Maintenance: 0.1-0.2 mg/kg IV repeat PRN OR Continuous infusion: 0.01-0.012 mg/kg/min IV
Route of Administration: Intravenous
Aliquots of 100 mkl whole heparinized blood of rocuronium-allergic patients (positive basophil activation test and skin test) were challenged at 37 C with buffer as a negative control, anti-IgE (Pharmingen,BDBioscience, Erembodegem, Belgium) as a positive control, serial dilutions of rocuronium (Esmeron, Organon, Brussels, Belgium, 0.2–2.0 x 10^3 mkg/ml), serial dilutions of sugammadex (Bridion; Merck Sharp & Dohme, Oss, The Netherlands) 0.2–2.0 x 10^3 mkg/ml and with a mixture of different concentrations of rocuronium and sugammadex. Flow cytometric analysis of basophils was performed using triple labelling with CD123-PE, HLA-DR-PerCP, CD63-FITC (BD Biosciences) and using monoclonal antihuman IgE (clone GE-1; Sigma-Aldrich Chemic GmBH, Steinheim, Germany), labelled with AlexaFluor 488 (Molecular Probes, Invitrogen, Paisley, UK). Samples were analysed on a flow cytometer (FACsCanto BD; Immunocytometry Systems, San Jose, CA, USA) and expressed as CD63-positive basophils. Samples were regarded as positive when CD63-reactive basophils were higher than 4%
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:15:21 UTC 2023
Edited
by admin
on Wed Jul 05 23:15:21 UTC 2023
Record UNII
I65MW4OFHZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROCURONIUM BROMIDE
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
ROCURONIUM BROMIDE [JAN]
Common Name English
ROCURONIUM BROMIDE [MI]
Common Name English
ROCURONIUM BROMIDE [VANDF]
Common Name English
(+)-ROCURONIUM BROMIDE
Common Name English
ROCURONIUM BROMIDE [EP MONOGRAPH]
Common Name English
rocuronium bromide [INN]
Common Name English
ZEMURON
Brand Name English
ROCURONIUM BROMIDE [USAN]
Common Name English
ORG 9426
Code English
1-Allyl-1-(3α,17β-dihydroxy-2β-morpholino-5α-androstan-16β-yl)pyrrolidinium bromide, 17-acetate
Common Name English
ESMERON
Brand Name English
ROCURONIUM BROMIDE [USP-RS]
Common Name English
ROCURONIUM BROMIDE [MART.]
Common Name English
PYRROLIDINIUM, 1-((2.BETA.,3.ALPHA.,5.ALPHA.,16.BETA.,17.BETA.)-17-(ACETYLOXY)-3-HYDROXY-2-(4-MORPHOLINYL)ANDROSTAN-16-YL)-1-(2-PROPENYL)-, BROMIDE
Common Name English
ROCURONIUM BROMIDE [USP MONOGRAPH]
Common Name English
ROCURONIUM BROMIDE [ORANGE BOOK]
Common Name English
ORG-9426
Code English
Rocuronium bromide [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QM03AC09
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
WHO-ATC M03AC09
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
NCI_THESAURUS C29696
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
Code System Code Type Description
WIKIPEDIA
ROCURONIUM BROMIDE
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
DAILYMED
I65MW4OFHZ
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
CAS
119302-91-9
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
MERCK INDEX
M9645
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY Merck Index
RXCUI
32521
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID7023566
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
ChEMBL
CHEMBL1201244
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
PUBCHEM
441351
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
EVMPD
SUB10353MIG
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
INN
6864
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
DRUG BANK
DBSALT000575
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
RS_ITEM_NUM
1604905
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
CHEBI
8885
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
FDA UNII
I65MW4OFHZ
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
NCI_THESAURUS
C47709
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
SMS_ID
100000080269
Created by admin on Wed Jul 05 23:15:21 UTC 2023 , Edited by admin on Wed Jul 05 23:15:21 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY